Amgen To Webcast Investor Meeting At Upcoming American Society Of Clinical Oncology Annual Meeting

  Amgen To Webcast Investor Meeting At Upcoming American Society Of Clinical
                           Oncology Annual Meeting

PR Newswire

THOUSAND OAKS, Calif., May 29, 2013

THOUSAND OAKS, Calif., May 29, 2013 /PRNewswire/ --Amgen (NASDAQ: AMGN) will
host a webcast investor meeting at the American Society of Clinical Oncology
(ASCO) Annual Meeting in Chicago on Saturday, June 1 at 7:00 p.m. CDT. Sean E.
Harper, M.D., executive vice president of Research and Development at Amgen,
along with members of Amgen's clinical development team and clinical
investigators, will participate at the investor meeting to discuss data being
presented at ASCO.

Live audio of the conference call will be simultaneously broadcast over the
Internet and will be available to members of the news media, investors and the
general public.

The webcast of the conference, as with other selected presentations regarding
developments in Amgen's business given by management at certain investor and
medical conferences, can be found on Amgen's website, www.amgen.com, under
Investors. Information regarding presentation times, webcast availability and
webcast links are noted on Amgen's Investor Relations Events Calendar. The
webcast will be archived and available for replay for at least 30 days after
the event.

About Amgen

Amgen discovers, develops, manufactures and delivers innovative human
therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first
companies to realize the new science's promise by bringing safe, effective
medicines from lab to manufacturing plant to patient. Amgen therapeutics have
changed the practice of medicine, helping people around the world in the fight
against serious illnesses. With a deep and broad pipeline of potential new
medicines, Amgen remains committed to advancing science to dramatically
improve people's lives. For more information, visit www.amgen.com and follow
us on www.twitter.com/amgen.

CONTACT: Amgen, Thousand Oaks
Ashleigh Koss, 805-313-6151 (media)
Arvind Sood, 805-447-1060 (investors)

(Logo: http://photos.prnewswire.com/prnh/20081015/AMGENLOGO)



SOURCE Amgen

Website: http://www.amgen.com